253 related articles for article (PubMed ID: 23149916)
1. Tasquinimod Is an Allosteric Modulator of HDAC4 survival signaling within the compromised cancer microenvironment.
Isaacs JT; Antony L; Dalrymple SL; Brennen WN; Gerber S; Hammers H; Wissing M; Kachhap S; Luo J; Xing L; Björk P; Olsson A; Björk A; Leanderson T
Cancer Res; 2013 Feb; 73(4):1386-99. PubMed ID: 23149916
[TBL] [Abstract][Full Text] [Related]
2. Third generation quinoline-3-carboxamide transcriptional disrupter of HDAC4, HIF-1α, and MEF-2 signaling for metastatic castration-resistant prostate cancer.
Isaacs JT; Dalrymple SL; Antony L; Marc Rosen D; Coleman IM; Nelson PS; Kostova M; Murray IA; Perdew GH; Denmeade SR; Akinboye ES; Brennen WN
Prostate; 2023 Nov; 83(15):1470-1493. PubMed ID: 37559436
[TBL] [Abstract][Full Text] [Related]
3. Anti-cancer potency of tasquinimod is enhanced via albumin-binding facilitating increased uptake in the tumor microenvironment.
Isaacs JT; Dalrymple SL; Rosen DM; Hammers H; Olsson A; Leanderson T
Oncotarget; 2014 Sep; 5(18):8093-106. PubMed ID: 25193858
[TBL] [Abstract][Full Text] [Related]
4. Nucleus accumbens-associated protein-1 promotes glycolysis and survival of hypoxic tumor cells via the HDAC4-HIF-1α axis.
Zhang Y; Ren YJ; Guo LC; Ji C; Hu J; Zhang HH; Xu QH; Zhu WD; Ming ZJ; Yuan YS; Ren X; Song J; Yang JM
Oncogene; 2017 Jul; 36(29):4171-4181. PubMed ID: 28319066
[TBL] [Abstract][Full Text] [Related]
5. Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors.
Olsson A; Björk A; Vallon-Christersson J; Isaacs JT; Leanderson T
Mol Cancer; 2010 May; 9():107. PubMed ID: 20470445
[TBL] [Abstract][Full Text] [Related]
6. Tasquinimod inhibits prostate cancer growth in bone through alterations in the bone microenvironment.
Magnusson LU; Hagberg Thulin M; Plas P; Olsson A; Damber JE; Welén K
Prostate; 2016 Mar; 76(4):383-93. PubMed ID: 26660725
[TBL] [Abstract][Full Text] [Related]
7. Interaction between p53 and Ras signaling controls cisplatin resistance via HDAC4- and HIF-1α-mediated regulation of apoptosis and autophagy.
Zhang X; Qi Z; Yin H; Yang G
Theranostics; 2019; 9(4):1096-1114. PubMed ID: 30867818
[TBL] [Abstract][Full Text] [Related]
8. HDAC4 protein regulates HIF1α protein lysine acetylation and cancer cell response to hypoxia.
Geng H; Harvey CT; Pittsenbarger J; Liu Q; Beer TM; Xue C; Qian DZ
J Biol Chem; 2011 Nov; 286(44):38095-38102. PubMed ID: 21917920
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of metastasis in a castration resistant prostate cancer model by the quinoline-3-carboxamide tasquinimod (ABR-215050).
Jennbacken K; Welén K; Olsson A; Axelsson B; Törngren M; Damber JE; Leanderson T
Prostate; 2012 Jun; 72(8):913-24. PubMed ID: 22287276
[TBL] [Abstract][Full Text] [Related]
10. Histone deacetylase 4 mediates SMAD family member 4 deacetylation and induces 5-fluorouracil resistance in breast cancer cells.
Yu SL; Lee DC; Son JW; Park CG; Lee HY; Kang J
Oncol Rep; 2013 Sep; 30(3):1293-300. PubMed ID: 23817620
[TBL] [Abstract][Full Text] [Related]
11. Metastasis-associated protein 1 enhances stability of hypoxia-inducible factor-1alpha protein by recruiting histone deacetylase 1.
Yoo YG; Kong G; Lee MO
EMBO J; 2006 Mar; 25(6):1231-41. PubMed ID: 16511565
[TBL] [Abstract][Full Text] [Related]
12. Transcriptional activation of hypoxia-inducible factor-1alpha by HDAC4 and HDAC5 involves differential recruitment of p300 and FIH-1.
Seo HW; Kim EJ; Na H; Lee MO
FEBS Lett; 2009 Jan; 583(1):55-60. PubMed ID: 19071119
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic control of HNF-4α in colon carcinoma cells affects MUC4 expression and malignancy.
Algamas-Dimantov A; Yehuda-Shnaidman E; Peri I; Schwartz B
Cell Oncol (Dordr); 2013 Apr; 36(2):155-67. PubMed ID: 23307400
[TBL] [Abstract][Full Text] [Related]
14. Reciprocal loop of hypoxia-inducible factor-1α (HIF-1α) and metastasis-associated protein 2 (MTA2) contributes to the progression of pancreatic carcinoma by suppressing E-cadherin transcription.
Zhu S; Deng S; He C; Liu M; Chen H; Zeng Z; Zhong J; Ye Z; Deng S; Wu H; Wang C; Zhao G
J Pathol; 2018 Jul; 245(3):349-360. PubMed ID: 29708271
[TBL] [Abstract][Full Text] [Related]
15. HDAC4 promotes nasopharyngeal carcinoma progression and serves as a therapeutic target.
Cheng C; Yang J; Li SW; Huang G; Li C; Min WP; Sang Y
Cell Death Dis; 2021 Feb; 12(2):137. PubMed ID: 33542203
[TBL] [Abstract][Full Text] [Related]
16. [Tasquinimod: How to act on microenvironment in metastatic prostate cancer].
Houédé N; Irani J
Prog Urol; 2015 May; 25(6):298-305. PubMed ID: 25684391
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of action of tasquinimod on the tumour microenvironment.
Raymond E; Dalgleish A; Damber JE; Smith M; Pili R
Cancer Chemother Pharmacol; 2014 Jan; 73(1):1-8. PubMed ID: 24162378
[TBL] [Abstract][Full Text] [Related]
18. Cyclin-dependent kinase inhibitor, P276-00, inhibits HIF-1α and induces G2/M arrest under hypoxia in prostate cancer cells.
Manohar SM; Padgaonkar AA; Jalota-Badhwar A; Rao SV; Joshi KS
Prostate Cancer Prostatic Dis; 2012 Mar; 15(1):15-27. PubMed ID: 22083267
[TBL] [Abstract][Full Text] [Related]
19. Long non-coding RNA histone deacetylase 4 antisense RNA 1 (HDAC4-AS1) inhibits HDAC4 expression in human ARPE-19 cells with hypoxic stress.
Pan J; Zhao L
Bioengineered; 2021 Dec; 12(1):2228-2237. PubMed ID: 34057022
[TBL] [Abstract][Full Text] [Related]
20. The quinoline-3-carboxamide anti-angiogenic agent, tasquinimod, enhances the anti-prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts.
Dalrymple SL; Becker RE; Isaacs JT
Prostate; 2007 May; 67(7):790-7. PubMed ID: 17373719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
